✓ checked
trust me, bro:
here is the receipt.
the claim
Metformin is considered a protective reagent against the development of some cancers.
the verdict
SUPPORTED
the evidence backs this
Recorded sources
9 sources for · 0 against
Is it true that Metformin is considered a protective reagent against the development of some cancers?
Yes. Extensive preclinical, epidemiological, and clinical evidence indicates that metformin exhibits significant antitumor and chemopreventive properties across multiple cancer types.
Verdict: SUPPORTED · 9 sources for, 0 against · Last checked
The analysis
The retrieved papers consistently support the claim that metformin functions as a protective or antineoplastic agent against the development and progression of various cancers, including breast, ovarian, colorectal, and head and neck cancers, primarily acting through AMPK/mTOR pathway modulation and metabolic regulation.
Evidence for · 9
Experimental and epidemiologic studies show that metformin reduces mutagenesis and possesses antitumor properties.
Get citation
Bost, F., Ben-Sahra, I., & Tanti, J. (2012). Prevention of Mutagenesis: New Potential Mechanisms of Metformin Action in Neoplastic Cells. doi.org. https://doi.org/10.1158/1940-6207.capr-12-0085
See more details
More for · 8
Metformin has shown robust benefits in reducing type 2 diabetes-related complications and potential utility in the antineoplastic setting.
Get citation
C, E., J, V., DI, M., & GI, O. (2026). Impact of type 2 diabetes on malignancies of the female reproductive system.. doi.org. https://doi.org/10.1016/j.mam.2026.101459
Metformin demonstrates antineoplastic activity and suppresses proliferative and migratory capacities in ovarian cancer cells.
Get citation
Biltekin, B., Karalok, M. H., Dumur, S., Mısırlıoglu, N. F., & Uzun, H. (2026). Combined Antineoplastic Effects of Metformin, Boric Acid and Resveratrol in SKOV3 Ovarian Cancer Cells. doi.org. https://doi.org/10.3390/biomedicines14030719
Preclinical and epidemiological studies suggest metformin exerts anti-tumor effects through insulin-dependent and independent pathways like AMPK activation.
Get citation
Y, Z., L, Z., K, Z., & Y, G. (2026). Metformin and oncogenic pathways: Crosstalk between energy sensing and tumor progression.. doi.org. https://doi.org/10.1016/j.mcp.2026.102068
Metformin use in breast cancer patients is associated with lower disease stage, fewer involved lymph nodes, and a better prognosis.
Get citation
E, B., M, M., M, J., Y, Z., & S, M. (2026). Impact of Metformin Use on Clinical and Pathological Outcomes in Breast Cancer Patients With Type 2 Diabetes.. doi.org. https://doi.org/10.1002/cnr2.70631
Metformin exhibits pleiotropic properties like anti-inflammatory and antiproliferative activities that position it as a promising therapeutic candidate for gastrointestinal cancers.
Get citation
SA, H., H, V., SM, K., S, K., S, F., D, R., A, H., & MH, H. (2026). Metformin as a Multifaceted Therapeutic Agent for Gastrointestinal Diseases: Mechanisms, Clinical Efficacy, and Future Directions.. doi.org. https://doi.org/10.1002/prp2.70257
Metformin is a prominent candidate for cancer drug repurposing, backed by preclinical and epidemiological evidence showing reduced cancer incidence.
Get citation
DJ, P., KJ, P., D, M., M, P., Z, D., I, Č., & JK, P. (2026). Comparison of Metformin Combinations with Other Repurposed Drugs in the Treatment of Hamster Fibrosarcoma: A Review.. doi.org. https://doi.org/10.3390/ph19081254
Metformin acts via AMPK/mTOR and immune reprogramming pathways to modulate colorectal cancer risk and act chemopreventively.
Get citation
Y, Y. & K, W. (2026). Pharmacological mechanisms and clinical impacts of antidiabetic drugs on colorectal cancer risk: a systematic review.. doi.org. https://doi.org/10.3389/fphar.2026.1849647
Metformin use is associated with increased overall survival probability and lower incidence risk in head and neck cancer patients.
Get citation
V, M., JF, F., A, M., M, B., & C, G. (2026). Effects of metformin on head and neck cancer: an umbrella review.. doi.org. https://doi.org/10.1186/s12885-026-16057-4
What does the evidence say?
The retrieved papers consistently support the claim that metformin functions as a protective or antineoplastic agent against the development and progression of various cancers, including breast, ovarian, colorectal, and head and neck cancers, primarily acting through AMPK/mTOR pathway modulation and metabolic regulation.
Receipt History
Anyone with this link can read the claim and its public receipt, including any
personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check
or guarantee a response time.
Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.
This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work
Terms · Privacy · How verdicts work